Lijie Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lijie Zhang has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Guize Feng
Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, PR China
3 shared publications- Ji Zhu
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China
3 shared publications Jin Fan
Department of Biostatistics, Fudan University Shanghai Cancer Center, Shanghai, China
3 shared publications- Xiaoyan Shen
Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China
3 shared publications Yirui Wang
Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, PR China
3 shared publicationsFandong Ren
Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Integrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer
Background: Neoadjuvant therapy (NAT) has shifted rectal cancer management toward organ preservation. However, achieving a complete response (CR) for “watch-and-wait” strategies is hindered by high response heterogeneity. Although immunotherapy-combined NAT has expanded the candidate pools, the predictive significance of molecular alterations remains unclear. Objectives: This study aimed to evaluate clinical and genomic profiles of rectal cancer patients undergoing NAT to identify response predictors and to develop a nomogram for estimating CR probability. Design: Retrospective, single-center cohort study. Methods: This study included 437 patients with rectal adenocarcinoma at Fudan University Shanghai Cancer Center between December 2019 and March 2023. Patients underwent paired tumor and germline genomic sequencing (887-gene panel) before NAT. Logistic and Cox regression analyses were performed to identify clinical and genetic risk factors associated with tumor response and long-term survival. Results: Of the 437 patients, 96.6% had microsatellite-stable (MSS) tumors. In the MSS locally advanced rectal cancer cohort (N = 307), the CR rate was 35.5%. Multivariate analysis identified immunotherapy-combined NAT (iTNT) (OR 4.41, 95% CI: 2.42–8.27), SYNE1 mutation (OR 2.12, 95% CI: 1.06–4.26), negative mesorectal fascia (MRF) status (OR 0.34, 95% CI: 0.17–0.66), and lower tumor location (OR 0.48, 95% CI: 0.27–0.84) as independent predictors of CR. KRAS mutation was the sole independent predictor of reduced disease-free survival (DFS; HR 1.93, 95% CI: (1.11–3.36), p = 0.020). KRAS G12D subtype was associated with the worst 2-year distant metastasis-free survival (71.3%) and exhibited a distinct predilection for lung metastasis. The clinical-genomic nomogram yielded strong discrimination (AUC = 0.705) and calibration, with favorable DCA net benefit. Conclusion: Clinical and genomic features jointly determine outcomes in MSS rectal cancer. SYNE1 mutation serves as a novel biomarker for CR, while KRAS mutations, especially the G12D subtype, identify patients at high risk for systemic relapse. The clinical-genomic nomogram facilitates individualized selection for organ-preservation strategies.
- 31 August 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Open AccessIntegrating clinical and genomic features to predict response to neoadjuvant therapy in microsatellite-stable rectal cancer
Background: Neoadjuvant therapy (NAT) has shifted rectal cancer management toward organ preservation. However, achieving a complete response (CR) for “watch-and-wait” strategies is hindered by high response heterogeneity. Although immunotherapy-combined NAT has expanded the candidate pools, the predictive significance of molecular alterations remains unclear. Objectives: This study aimed to evaluate clinical and genomic profiles of rectal cancer patients undergoing NAT to identify response predictors and to develop a nomogram for estimating CR probability. Design: Retrospective, single-center cohort study. Methods: This study included 437 patients with rectal adenocarcinoma at Fudan University Shanghai Cancer Center between December 2019 and March 2023. Patients underwent paired tumor and germline genomic sequencing (887-gene panel) before NAT. Logistic and Cox regression analyses were performed to identify clinical and genetic risk factors associated with tumor response and long-term survival. Results: Of the 437 patients, 96.6% had microsatellite-stable (MSS) tumors. In the MSS locally advanced rectal cancer cohort (N = 307), the CR rate was 35.5%. Multivariate analysis identified immunotherapy-combined NAT (iTNT) (OR 4.41, 95% CI: 2.42–8.27), SYNE1 mutation (OR 2.12, 95% CI: 1.06–4.26), negative mesorectal fascia (MRF) status (OR 0.34, 95% CI: 0.17–0.66), and lower tumor location (OR 0.48, 95% CI: 0.27–0.84) as independent predictors of CR. KRAS mutation was the sole independent predictor of reduced disease-free survival (DFS; HR 1.93, 95% CI: (1.11–3.36), p = 0.020). KRAS G12D subtype was associated with the worst 2-year distant metastasis-free survival (71.3%) and exhibited a distinct predilection for lung metastasis. The clinical-genomic nomogram yielded strong discrimination (AUC = 0.705) and calibration, with favorable DCA net benefit. Conclusion: Clinical and genomic features jointly determine outcomes in MSS rectal cancer. SYNE1 mutation serves as a novel biomarker for CR, while KRAS mutations, especially the G12D subtype, identify patients at high risk for systemic relapse. The clinical-genomic nomogram facilitates individualized selection for organ-preservation strategies.
- 12 January 2025
- Published by Elsevier in Phytomedicine
- Vol. 138, 156384
Paeoniflorin protects the vascular endothelial barrier in mice with sepsis by activating RXRα signaling
- 12 January 2025
- Published by Elsevier in Phytomedicine
- Vol. 138, 156384
Paeoniflorin protects the vascular endothelial barrier in mice with sepsis by activating RXRα signaling
- 10 April 2024
- Published by Elsevier in Phytomedicine
- Vol. 129, 155615
Gentisic acid prevents colorectal cancer metastasis via blocking GPR81-mediated DEPDC5 degradation
- 10 April 2024
- Published by Elsevier in Phytomedicine
- Vol. 129, 155615
Gentisic acid prevents colorectal cancer metastasis via blocking GPR81-mediated DEPDC5 degradation
- Open Access
- 14 December 2023
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 52 (1) , S141
333: ENHANCING HAND HYGIENE COMPLIANCE IN CRITICAL CARE WITH YOLOV5-GC
- 14 December 2023
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 52 (1) , S141
Open Access333: ENHANCING HAND HYGIENE COMPLIANCE IN CRITICAL CARE WITH YOLOV5-GC
- Open Access
- 1 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (35) , eadh5016
Inhibiting sorting nexin 10 promotes mucosal healing through SREBP2-mediated stemness restoration of intestinal stem cells
Intestinal stem cell (ISC) is a promising therapeutic target for inflammatory bowel disease. Cholesterol availability is critical for ISC stemness. Low plasma cholesterol is a typical feature of Crohn’s disease (CD); however, its impact on mucosal healing remains unclear. Here, we identified an essential role of sorting nexin 10 (SNX10) in maintaining the stemness of ISCs. SNX10 expression in intestinal tissues positively correlates with the severity of human CD and mouse colitis. Conditional SNX10 knockout in intestinal epithelial cells or ISCs promotes intestinal mucosal repair by maintaining the ISC population associated with increased intracellular cholesterol synthesis. Disassociation of ERLIN2 with SCAP by SNX10 deletion enhances the activation of SREBP2, resulting in increased cholesterol biosynthesis. DC-SX029, a small-molecule inhibitor of SNX10, was used to verify the druggable potential of SNX10 for the treatment of patients with CD. Our study provides a strategy for mucosal healing through SREBP2-mediated stemness restoration of ISCs.
- 1 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (35) , eadh5016
Open AccessInhibiting sorting nexin 10 promotes mucosal healing through SREBP2-mediated stemness restoration of intestinal stem cells
Intestinal stem cell (ISC) is a promising therapeutic target for inflammatory bowel disease. Cholesterol availability is critical for ISC stemness. Low plasma cholesterol is a typical feature of Crohn’s disease (CD); however, its impact on mucosal healing remains unclear. Here, we identified an essential role of sorting nexin 10 (SNX10) in maintaining the stemness of ISCs. SNX10 expression in intestinal tissues positively correlates with the severity of human CD and mouse colitis. Conditional SNX10 knockout in intestinal epithelial cells or ISCs promotes intestinal mucosal repair by maintaining the ISC population associated with increased intracellular cholesterol synthesis. Disassociation of ERLIN2 with SCAP by SNX10 deletion enhances the activation of SREBP2, resulting in increased cholesterol biosynthesis. DC-SX029, a small-molecule inhibitor of SNX10, was used to verify the druggable potential of SNX10 for the treatment of patients with CD. Our study provides a strategy for mucosal healing through SREBP2-mediated stemness restoration of ISCs.
- Open Access
- 19 January 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Publisher Correction: Serum metabolic traits reveal therapeutic toxicities and responses of neoadjuvant chemoradiotherapy in patients with rectal cancer
- 19 January 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessPublisher Correction: Serum metabolic traits reveal therapeutic toxicities and responses of neoadjuvant chemoradiotherapy in patients with rectal cancer
- Open Access
- 20 December 2022
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 43 (5) , 792-800
Study on the relationship between vitamin D level and macrophage typing in patients with type 2 diabetes mellitus
Objective: Population studies have shown that vitamin D (VitD) deficiency is associated with an increased incidence of type 2 diabetes mellitus (T2DM), VitD deficiency is a potential risk factor for T2DM, and the proportion of M1-type macrophages and M2-type macrophages in T2DM patients is imbalanced. Another study reported that VitD can affect the differentiation of macrophages into M1 and M2 types. However, there is no definitive result about the correlation between plasma VitD levels and macrophage typing in patients with T2DM. Whether VitD affects the progression of T2DM by regulating the polarization type of macrophages and the specific regulatory mechanism is not very clear. Therefore, we carried out the following research. Methods: We first used flow cytometry to detect the proportions of M1 and M2 macrophages in peripheral blood of T2DM patients with different VitD levels. Furthermore, we used ELISA to detect the inflammatory factors affecting macrophage differentiation in patients’ plasma, including IL-6 secreted by M1-type macrophages and TGF-β secreted by M2-type macrophages. Mononuclear cells were separated from human peripheral blood with immunomagnetic beads, cultured in vitro, and treated with different concentrations of VitD, and the ratio of differentiation into M1 and M2 macrophages was detected by flow cytometry. Results: With the increase of serum 25(OH)D levels in patients with T2DM, the proportion of M1 and M2 macrophages in peripheral blood decreased, that is, the polarized phenotype of macrophages was more inclined to M2 type, while plasma IL-6 gradually decreased, and TGF-β gradually increased. In addition, VitD can promote the differentiation of CD14-positive monocytes cultured in vitro into M2 macrophages. Conclusions: When the level of VitD in T2DM patients is low, there are more M1-type macrophages in peripheral blood, and when the level of VitD is increased, M2-type macrophages are increased. Changes in related inflammatory factors were also consistent. In vitro culture of monocytes further confirmed that VitD can promote the differentiation of macrophages to M2 type in T2DM patients.
- 20 December 2022
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 43 (5) , 792-800
Open AccessStudy on the relationship between vitamin D level and macrophage typing in patients with type 2 diabetes mellitus
Objective: Population studies have shown that vitamin D (VitD) deficiency is associated with an increased incidence of type 2 diabetes mellitus (T2DM), VitD deficiency is a potential risk factor for T2DM, and the proportion of M1-type macrophages and M2-type macrophages in T2DM patients is imbalanced. Another study reported that VitD can affect the differentiation of macrophages into M1 and M2 types. However, there is no definitive result about the correlation between plasma VitD levels and macrophage typing in patients with T2DM. Whether VitD affects the progression of T2DM by regulating the polarization type of macrophages and the specific regulatory mechanism is not very clear. Therefore, we carried out the following research. Methods: We first used flow cytometry to detect the proportions of M1 and M2 macrophages in peripheral blood of T2DM patients with different VitD levels. Furthermore, we used ELISA to detect the inflammatory factors affecting macrophage differentiation in patients’ plasma, including IL-6 secreted by M1-type macrophages and TGF-β secreted by M2-type macrophages. Mononuclear cells were separated from human peripheral blood with immunomagnetic beads, cultured in vitro, and treated with different concentrations of VitD, and the ratio of differentiation into M1 and M2 macrophages was detected by flow cytometry. Results: With the increase of serum 25(OH)D levels in patients with T2DM, the proportion of M1 and M2 macrophages in peripheral blood decreased, that is, the polarized phenotype of macrophages was more inclined to M2 type, while plasma IL-6 gradually decreased, and TGF-β gradually increased. In addition, VitD can promote the differentiation of CD14-positive monocytes cultured in vitro into M2 macrophages. Conclusions: When the level of VitD in T2DM patients is low, there are more M1-type macrophages in peripheral blood, and when the level of VitD is increased, M2-type macrophages are increased. Changes in related inflammatory factors were also consistent. In vitro culture of monocytes further confirmed that VitD can promote the differentiation of macrophages to M2 type in T2DM patients.
- Open Access
- 17 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
Serum metabolic traits reveal therapeutic toxicities and responses of neoadjuvant chemoradiotherapy in patients with rectal cancer
Neoadjuvant chemoradiotherapy (nCRT) has become the standard treatment for patients with locally advanced rectal cancer (LARC). Therapeutic efficacy of nCRT is significantly affected by treatment-induced diarrhea and hematologic toxicities. Metabolic alternations in cancer therapy are key determinants to therapeutic toxicities and responses, but exploration in large-scale clinical studies remains limited. Here, we analyze 743 serum samples from 165 LARC patients recruited in a phase III clinical study using untargeted metabolomics and identify responsive metabolic traits over the course of nCRT. Pre-therapeutic serum metabolites successfully predict the chances of diarrhea and hematologic toxicities during nCRT. Particularly, levels of acyl carnitines are linked to sex disparity in nCRT-induced diarrhea. Finally, we show that differences in phenylalanine metabolism and essential amino acid metabolism may underlie distinct therapeutic responses of nCRT. This study illustrates the metabolic dynamics over the course of nCRT and provides potential to guide personalized nCRT treatment using responsive metabolic traits.
- 17 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
Open AccessSerum metabolic traits reveal therapeutic toxicities and responses of neoadjuvant chemoradiotherapy in patients with rectal cancer
Neoadjuvant chemoradiotherapy (nCRT) has become the standard treatment for patients with locally advanced rectal cancer (LARC). Therapeutic efficacy of nCRT is significantly affected by treatment-induced diarrhea and hematologic toxicities. Metabolic alternations in cancer therapy are key determinants to therapeutic toxicities and responses, but exploration in large-scale clinical studies remains limited. Here, we analyze 743 serum samples from 165 LARC patients recruited in a phase III clinical study using untargeted metabolomics and identify responsive metabolic traits over the course of nCRT. Pre-therapeutic serum metabolites successfully predict the chances of diarrhea and hematologic toxicities during nCRT. Particularly, levels of acyl carnitines are linked to sex disparity in nCRT-induced diarrhea. Finally, we show that differences in phenylalanine metabolism and essential amino acid metabolism may underlie distinct therapeutic responses of nCRT. This study illustrates the metabolic dynamics over the course of nCRT and provides potential to guide personalized nCRT treatment using responsive metabolic traits.
- Open Access
- 1 December 2021
- Published by Elsevier in Endocrine and Metabolic Science
- Vol. 5, 100106
Hypoparathyroidism Associated with the DNA Variants in Non-Coding Sequence Region of Calcium-Sensing Receptor
- 1 December 2021
- Published by Elsevier in Endocrine and Metabolic Science
- Vol. 5, 100106
Open AccessHypoparathyroidism Associated with the DNA Variants in Non-Coding Sequence Region of Calcium-Sensing Receptor
- 1 November 2021
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 212, 106439
Multi-view features integrated 2D\3D Net for glomerulopathy histologic types classification using ultrasound images
- 1 November 2021
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 212, 106439
Multi-view features integrated 2D\3D Net for glomerulopathy histologic types classification using ultrasound images